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Infergen Stimulated Macrophages 
Restrict Mycobacterium tuberculosis 
Growth by Autophagy and Release 
of Nitric Oxide
Susanta Pahari1,2, Nargis Khan1, Mohammad Aqdas1, Shikha Negi1, Jagdeep Kaur2 & 
Javed N. Agrewala1
IFN alfacon-1 (Infergen) is a synthetic form of Interferon (IFN)-α2b. Infergen has immunomodulatory 
activity and is effective against hepatitis C virus. However, the effect of Infergen (IFG) on Mycobacterium 
tuberculosis (Mtb) has not yet been reported. Therefore, for the first time, we have studied the influence 
of IFG in constraining the survival of Mtb in human macrophages. We observed that IFG significantly 
enhanced the maturation and activation of macrophages. Further, it substantially augmented the 
secretion of IL-6, nitric oxide (NO) and antigen uptake. Moreover, macrophages exhibited remarkably 
higher bactericidal activity, as evidenced by reduction in the Mtb growth. Infergen-mediated 
mechanism was different from the type-1 interferons; since it worked through the activation of NF-κB, 
phosphorylation of STAT-3 and Akt-PI3K that improved the bactericidal activity through autophagy  
and NO release. In future, IFG immunotherapy can be a novel strategy for treating patients and 
controlling TB.
In spite of the fact that effective drugs like rifampicin, isoniazid, ethambutol, pyrazinamide, etc., are available to 
treat tuberculosis (TB); the disease continues to inflict a detrimental impact on public health worldwide. Nearly 
one third of the world population is infected with Mycobacterium tuberculosis (Mtb) and about 1% develops 
new infection annually, accounting for total 9.6 million new cases1. In 2014, there were about 1.5 million allied 
deaths; typically occurring in the developing countries [WHO, 2015]. The problem is further aggravated with the 
emergence of MDR-TB (multi-drug-resistant tuberculosis), XDR (extensively drug-resistant tuberculosis) and 
TDR (totally drug-resistant tuberculosis) strains of Mtb, AIDS-pandemic and failure of BCG vaccine2–4. Hence, 
there is an urgent need to identify newer drugs and develop radical changes in the current therapeutic strategies 
to control TB.
Interferons (IFNs) are naturally occurring immunomodulatory cytokines. Type-I IFNs are very well-known 
for their anti-viral activity5–9. Recently, a non-naturally occurring type-I IFN known as IFN alfacon-1 or Infergen 
(IFG) has been approved against hepatitis C virus10,11. Infergen is quite distinct from type-I IFNs, since it is 
derived from the sequences selected from several α -IFNs (interferon α 2a and interferon α 2b) and then producing 
a consensus gene product12. The role of type-1 IFNs against Mtb has not been clear so far13–16. However like IFN-γ , 
type-1 IFNs are reported to kill Mtb by bolstering host immunity13–16.
Although, IFG shares biological and pharmacological properties with type 1 IFNs, it follows a unique and dis-
tinct signaling pathway. Infergen exhibits potent immunomodulatory activity in human cells17. Furthermore, it is 
known to control viral infection by enhancing the activation of T cells through an augmented viral peptide pres-
entation by antigen presenting cells (APCs). Unfortunately, nothing has been reported regarding the therapeutic 
aspect of IFG on Mtb. Therefore, we thought that it would be interesting to study the impact of IFG in restricting 
the intracellular survival of Mtb and the mechanism involved therein.
Autophagy plays an essential role in protection against Mtb18. It targets the Mtb antigens to lysosomes for their 
degradation and clearance. Further, autophagy enhances the antigen presenting ability of APCs to T cells19,20. 
At the same time, it inhibits detrimental inflammatory responses21. Nitric oxide (NO) is known to confine the 
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growth of Mtb22. Taking into account these evidences, we were interested to monitor the influence of IFG on 
the activation of Mtb infected macrophages, thereby restricting the survival of the Mtb. It was quite fascinating 
to observe that IFG stimulated macrophages displayed significantly improved skill to restrict the intracellular 
growth of Mtb. The mechanism involved was through the augmentation of autophagy and release of NO. Both 
these pathways are considered crucial in curbing the growth of Mtb. Therefore, this study illustrates that IFG may 
have enough potential to work as an immunotherapeutic agent against TB.
Results
IFG restricts the intracellular survival of Mtb. Mtb not only infects macrophages but also it can survive 
in the hostile environment of these cells23,24. Thus, in the initial phase of the study, we investigated the impact of 
IFG on avirulent strain of Mtb H37Ra infected THP-1 macrophages (H37Ra-Mϕ ). It was quite exciting to note 
that IFG stimulated macrophages (Mϕ IFG) showed significant (p < 0.0001) reduction in the intracellular survival 
of Mycobacterium, as compared to unstimulated control [Fig. 1A]. The decrease in the CFUs was observed in a 
dose dependent fashion. Likewise, substantial (p < 0.0008) decline in the growth of virulent strain H37Rv (Mtb) 
was noticed [Fig. 1B]. Furthermore, we proved the above event through time-point kinetics by demonstrating a 
extensive (p < 0.0001) increase in Mtb killing (GFP-H37Ra) by flow cytometry assay [Fig. 1C]. Thus, validating 
the potent role of IFG in inhibiting the growth of both virulent and avirulent Mtb. The concentration of 64 ng/ml 
of IFG showed the maximum intracellular killing of Mtb and was not toxic to Mϕ and human peripheral blood 
mononuclear cells (PBMCs) [Fig. 1A and Fig. S1A–C]. Hence, this dose was chosen in all the subsequent 
experiments.
IFG augments the secretion of cytokines. IL-6 is a major cytokine produced by macrophages in 
response to intracellular pathogens25. This cytokine plays an important role in T cell activation and inhibition 
of the growth of Mtb25–31. IFG stimulated H37Ra infected Mϕ produced considerably (p < 0.001) higher level of 
IL-6, as compared to unstimulated (no Infergen) macrophages infected with H37Ra [Fig. 1D]. The increase in 
IL-6 was observed in a dose dependent manner. Further, these results were corroborated by IL-6 gene expression 
by RT-qPCR [Fig. 1E]. Additionally, we confirmed these results by observing a significant (p < 0.01) increase 
in the level of IL-6 and IFN-γ by IFG stimulated H37Ra infected macrophages isolated from human PBMCs 
[Fig. 1F,G]. Infergen is reported to promote Th1 polarization32. No noticeable change was seen in IL-1β, TGF-β, 
IL-10 and TNF-α genes expression [Fig. S2A–D].
IFG upregulates the expression of CD80, CD86 and HLA-DR. It has been reported that signaling 
through IFN-α /β can activate macrophages and other cells of the immune system during viral infection31–35. 
Further, MHC and costimulatory molecules expressed on the surface of the macrophages are crucial for the opti-
mum activation of T cells. It was noticed that Mtb-infected IFG stimulated THP-1 macrophages (Mtb-Mϕ -IFG) 
exhibited substantially (p < 0.02) higher expression of costimulatory molecules CD40 (p < 0.0004), CD80 
(p < 0.0001), CD86 (p < 0.02) and MHC-II (HLA-DR) (p < 0.003) [Fig. 2A–D and Fig. S3A–D]. These results 
were substantiated using CD11b+ human macrophages. We observed that IFG induces significant upregulation 
of CD80 (p < 0.01), CD86 (p < 0.05), compared to unstimulated controls [Fig. 2E,F and Fig. S3E,F]. Thus, our 
data suggest that IFG not only augments the activation and maturation of Mtb infected Mϕ differentiated from 
THP-1, but also macrophages isolated from human peripheral blood.
We further checked the activation status of other immune cells like B cells and T cells. As compared to 
untreated B cells, IFG treated B cells displayed a higher expression of CD80, CD86 and HLA-DR, [Fig. S4A–F]. 
We also noted significant (p < 0.01) upregulation of the activation marker CD25 on CD8 T cells treated with 
IFG [Fig. S5A]. Moreover, IFG incubated CD8 T cells showed substantial improvement (p < 0.01) in their ability 
to lyse the target cells [Fig. S5B]. Furthermore, IFG induced significant (p < 0.05) proliferation of PHA elicited 
human PBMCs [Fig. S5C]. These results designate that IFG not only stimulates the macrophages, but also B cells 
and CD8 T cells.
IFG activated macrophages show enhancement in antigen uptake. Macrophages are extremely 
efficient APCs responsible for phagocytosis. Therefore, we were curious to check whether IFG stimulated mac-
rophages acquire an enhanced capacity to phagocytose Mtb. Consequently, we stimulated macrophages with 
IFG and then infected them with Mtb. The extracellular bacteria were removed by extensive washings and subse-
quently treated with amikacin. Later, the cells were lysed and bacterial growth was enumerated by CFU plating. 
Remarkably, IFG significantly (p < 0.05) improved the ability of macrophages to phagocytose H37Ra, compared 
to unstimulated control [Fig. 3A]. These results were further supported by increased uptake of other mycobac-
terial strains M. smegmatis [Fig. 3B] and Mtb-H37Rv [Fig. 3C]. Furthermore, our flow cytometry and confocal 
microscopy experiments substantiated higher uptake of GFP+-H37Ra by IFG stimulated Mϕ [Fig. 3D,E and 
Fig. S6A,B]. The Z-stack [Fig. S6C] and live imaging videos [Fig. S6D, video 1, 2] also confirmed the presence 
of GFP+-Mtb inside the macrophages. In addition, we validated the higher uptake capacity of GFP+-H37Ra by 
IFG stimulated Mϕ through time point kinetics assay by flow cytometry [Fig. 3F]. Thus, these results signify the 
potential role of IFG in enhancing the phagocytosis by macrophages.
Induction of iNOS expression by IFG is necessary for autophagy. We next monitored the mecha-
nism of action operating in IFG stimulated cells in restricting Mtb survival. Intriguingly, we observed that inhi-
bition in the growth of Mtb by IFG stimulated cells was operating through NO production, as evidenced by an 
increase in the expression of INOS by RT-qPCR [Fig. 4A], as well as through expression of iNOS in the cytosol by 
Western blotting experiments [Fig. 4B]. Further, Mtb infected Mϕ on stimulation with IFG produced remarkably 
more nitric oxide (NO), as compared to either unstimulated or infected control macrophages [Fig. 4C]. Nitric 
oxide is an established indicator of bactericidal activity36. We substantiated the specificity of the induction of iNOS 
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Figure 1. IFG stimulated macrophages show augmented killing of Mtb. Macrophages were infected for 4 h 
with the mycobacterial strains [A] H37Ra; [B] H37Rv. Later, cells were stimulated with the indicated doses of 
IFG for 24 h. The infected macrophages were lysed and CFUs were enumerated after 21d. Infected macrophages 
treated with INH (25 μ g/ml) were used as positive control. [C] Time-point kinetics of GFP-H37Ra after 
4 h infection. This was followed by stimulation with IFG for 24 h and 48 h. The flow cytometry data (iMFI) 
represented through the line diagrams as mean ± SEM are representative of two independent experiments. 
[D] Supernatants of the H37Ra infected macrophages stimulated with IFG were collected after 24 h for the 
estimation of IL-6 by ELISA; [E] RNA was isolated after 6 h to monitor the expression of IL-6 by RT-qPCR. 
Data depicted as bar diagram are mean ± SEM of 4 individual wells and representative of four independent 
experiments. **p < 0.001, ***p < 0.0001. [F,G] Macrophages isolated from human PBMCs were infected with 
Mtb for 4 h. Later, they were stimulated with IFG for 24 h and the supernatants were collected for the estimation 
of IFN-γ and IL-6. UI: uninfected control; US: Mtb infected macrophages; IFG: Mtb infected and IFG  
(64 ng/ml) stimulated macrophages; INH: Mtb infected macrophages treated with isoniazid. Data represented as 
the mean ± SEM are of four wells and two independent experiments. **p ≤ 0.006, ***p ≤ 0.0006, ****p < 0.0001.
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by treating Mtb infected macrophages with iNOS inhibitor [(N-monomethyl-L-arginine), NM]. Interestingly, we 
observed significant decline in the NO production (p < 0.0001) and increase in the bacterial CFUs (p < 0.05) 
upon treatment of Mtb-Mϕ IFG with NM [Fig. 4C,D]. We also showed that there was downregulation in the auto-
phagy marker LC3, when iNOS was inhibited by NM [Fig. 4E]. Thus, establishing that iNOS activity is required 
for autophagy. Furthermore, autophagy inhibitor 3 methyl adenine (3MA) was used to unambiguously establish 
the induction of autophagy in Mtb infected Mϕ treated with IFG [Fig. 4E]. Rapamycin was used as a positive con-
trol. Moreover, blocking of Akt-PI3K and NF-кB pathways by their respective inhibitors, substantially reduced 
the secretion of NO [Fig. 4F].
Autophagy plays a fundamental role in inhibiting the intracellular survival of Mtb37. Interestingly, IFG stimu-
lation exhibited higher conversion of LC3I to LC3II, a hallmark of autophagy. We observed further amplification 
of autophagy by rapamycin treatment of the infected macrophages stimulated with IFG [Fig. 5A]. Thus corrobo-
rating the IFG induced autophagy. Additionally, blocking of Akt and PI3K pathways by their respective inhibitors 
inhibited the induction of autophagy [Fig. 5B]. Furthermore, augmentation (p < 0.0001) of the autophagy genes 
ATG5, ATG7 and BECLIN1, categorically established the involvement of autophagy [Fig. 5C–E]. Finally, we ver-
ified this finding by observing the over expression of autophagy influx by LC3 puncta formation in GFP-H37Ra 
infected macrophages through confocal microscopy after IFG and rapamycin treatment [Fig. 5F,G]. We observed 
that virulent and avirulent mycobacteria have similar responses with respect to autophagy. Interestingly, we also 
observed that IFG itself has an ability to induce autophagy influx in macrophages (Fig. S7A,B). Likewise, the 
acidic vacuoles were stained with acridine orange dye to show the induction of autophagy [Fig. 5H,I]. We also 
monitored autophagy by treating cells (infected and IFG stimulated) with rapamycin and correlated this with NO 
Figure 2. IFG upregulates the expression of CD40, CD80, CD86, and HLA-DR on the Mtb infected 
macrophages. [A–D] Macrophages; [E,F] Human PBMCs were infected with Mtb for 4 h and subsequently 
stimulated with IFG (64 ng/ml) for 24 h. Later, expression of CD40, CD80, CD86, and HLA-DR was evaluated 
by flow cytometry on the [A–D] macrophages; [E,F] CD11b gated PBMCs macrophages. The flow cytometry 
data (iMFI) represented through bar diagrams as mean ± SEM are representative of two independent 
experiments. UI: uninfected macrophages; UI + IFG: uninfected macrophages stimulated with IFG; US: Mtb 
infected macrophages; Infected + IFG: Mtb infected and IFG stimulated macrophages. *p ≤ 0.0285, **p < 0.003, 
***p < 0.0004, ****p < 0.0001.
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production and CFU burden [Fig. 5J,K]. Autophagy specific inhibitors 3MA and chloroquine (CQ) were used to 
establish the role of autophagy in restricting the growth of Mtb by IFG stimulated Mϕ . Substantial (p < 0.0001) 
reduction in the secretion of NO and increase in the survival of Mtb was noticed [Fig. 5L,M]. Thus, these results 
signify that the function of iNOS and autophagy are interlinked with each other and are possible mechanism 
operating in Mϕ IFG in constraining the Mtb growth.
IFG induces the phosphorylation of STAT-3 and activates Akt-PI3K pathway. It has been well 
established that IFN-α /β interacts with its receptor IFNAR and activates tyrosine kinase Jak-1 along with 
Figure 3. Signaling through IFG enhances phagocytosis. Macrophages stimulated with IFG for 24 h were 
infected with [A] H37Ra; [B] M. smegmatis; [C] H37Rv; [D,E] GFP-H37Ra. After 4 h, cells were lysed and 
bacterial uptake was monitored by [A–C] CFUs. [D] Flow cytometry; [E] confocal microscopy. [A–C] The 
data (mean ± SEM) shown as bar diagrams indicate bacterial uptake. [D] The data in the inset of histograms 
shown as % cells/MFI denote bacterial uptake. [F] The macrophages stimulated with IFG for 24 h and thereafter 
infected with GFP-H37Ra for 4 h. Time-point kinetics of bacterial uptake by macrophages was measured by 
flow cytometry. The flow cytometry data (iMFI) represented through the line diagrams as mean ± SEM are 
representative of two independent experiments. IFG: infected macrophages stimulated with Infergen; US: 
infected macrophages (not stimulated with IFG); DIC: differential interference contrast. Image magnification: 
60x. Data are representative of two independent experiments. *p < 0.05, **p < 0.003, ***p < 0.0004, 
****p < 0.0001.
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Figure 4. IFG restricts the intracellular survival of Mtb through the induction of iNOS. Macrophages 
were infected with Mtb for 4 h. Later, cells were stimulated with IFG (64 ng/ml) for 24 h and monitored for the 
expression of [A] INOS gene by RT-qPCR; [B] iNOS by Western blotting and values [fold change] are shown 
through densitometry analysis. [C,D] The specificity of NO production and its role in Mtb killing is proven by 
NO inhibitor NM. The estimation of [C] NO was done by Griess method and [D] Mtb killing by CFUs. The 
impact of autophagy in the inhibition of the growth of Mtb was ascertained by the [E] conversion of LC3-I to 
LC3-II by Western blotting and densitometry values are shown as fold change. Actin was used as a loading 
control. [F]. The secretion of NO was inhibited by treating the cells with the inhibitors of Akt and NF-κ B. 
LPS was used as a positive control. The specificity of autophagy was ascertained by blocking the conversion of 
LC3-1 into LC3-II by its inhibitors 3MA and NM. Rapamycin is used as a positive control of autophagy. The 
fold change was calculated considering the value of infected controls as 1. The data are representative of 2–4 
independent experiments. UI: uninfected macrophages; Infected: infected macrophages and unstimulated (no 
IFG); IFG: Mtb infected macrophages and IFG stimulated, NM: N-monomethyl-L-arginine, 3MA: 3 methyl 
adenine. *p < 0.05, **p < 0.01, ****p < 0.0001.
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Tyk-238,39. Jak-1 stimulates and phosphorylates STAT-1/STAT-3. As a result, Akt is activated through STAT-3 
along with PI3K and translocates into the nucleus. Further, it helps in delivering survival signal through the 
activation of NF-κ B. It has been reported that like IFN-α /β , IFG exhibits affinity for IFNAR and activates tyros-
ine kinase Jak-1 along with Tyk-2. Therefore, we investigated the mechanism involved in IFG-mediated sig-
nalling events responsible for activating macrophages to restrict the intracellular growth of Mtb. Mtb infected 
macrophages were stimulated with IFG and phosphorylation of STAT-3, PI3K and Akt molecules were monitored 
by Western blotting in the cytosolic extract. Noticeable augmentation in the phosphorylation of STAT-3, PI3K 
and Akt was observed in the Mϕ IFG [Fig. 6A–C]. The decrease in the phosphorylation of STAT-3 and PI3K 
was checked in Mϕ -IFG by treating with their respective inhibitors [Fig. 6A,B]. Further, augmentation in the 
Figure 5. The mechanism involved in controlling the growth of Mtb by IFG is through autophagy. 
Macrophages were infected with Mtb (H37Rv) for 4 h. Later, cells were stimulated with IFG (64 ng/ml) for 24 h 
and monitored for [A] the augmentation in the IFG induced autophagy by rapamycin through conversion of 
LC3-I to LC3-II by Western blotting. The densitometry values are shown as fold change. [B] The specificity of 
autophagy was determined by blocking Akt-PI3K pathway by their respective inhibitors. Rapamycin is used 
as a positive control of autophagy and actin as a loading control. The fold change was calculated considering 
the value of infected controls as 1. [C–E] Upregulation in the expression of autophagy markers [C] ATG5; 
[D] ATG7; [E] BECLIN 1 was done by RT-qPCR and the results are represented as relative expression (fold 
change). The fold change was calculated considering the value of uninfected controls as 1. [F,G] The induction 
and over expression of autophagy influx by LC3 puncta formation through confocal microscopy after IFG+ 
rapamycin treatment in GFP-H37Ra infected macrophages. The cells were infected with GFP-H37Ra [green] 
and stained for the expression of LC3 with anti-LC3 Abs [red], along with nucleus with DAPI dye [blue]. The 
frequency of puncta formation was enumerated using 4–5 different microscopic fields and the percent of cells 
with LC3 puncta [mean ± SEM] are presented as bar diagram. [H,I] Acidic vacuole formation was performed 
by acridine orange staining and fluorescence microscopy. The data [mean ± SEM] displayed as percent 
positive vacuole forming cells [orange] are from five different microscopic fields. The specificity of autophagy 
was determined by blocking its function by autophagy inhibitors [J,K] 3MA and [L,M] CQ; as observed by 
the change in the yield of NO and survival of Mtb. Rapamycin was used as a positive control. The data are 
denoted as mean ± SEM for NO [μ M] and H37RV [CFU/ml]. The results are representative of 2–4 independent 
experiments. UI: uninfected, US: infected, but not stimulated with IFG, IFG: Mtb infected and IFG stimulated, 
NM: N-monomethyl-L-arginine, 3MA: 3 methyl adenine, CQ: Chloroquine. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001.
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Figure 6. IFG signaling of the macrophages induces phosphorylation of STAT-3 through Akt-PI3K 
pathway and bolsters NF-κB nuclear translocation. Mtb infected macrophages were cultured with IFG. The 
cell lysate (cytosolic extract) was prepared and Western blotting was performed to monitor the expression of 
[A] pSTAT-3; [B] pPI3K; [C] pAkt; [D] Bcl-xL; [E] pSTAT-1. [F,G] NF-κ B was detected using nuclear extract 
by EMSA and densitometry values are represented by bar diagram as a fold change (mean ± SEM). [H] The 
translocation of NF-κ B from cytosol [US] to nucleus [IFG] was further validated by confocal microscopy 
using IFG stimulated Mtb infected macrophages. The green fluorescence indicates NF-κ B marker p65 and blue 
signifies the nucleus staining with Hoechst dye (magnification: 100x). LPS is used as a positive control. US: 
infected macrophages [no IFG]; IFG: infected macrophages treated with IFG. Data are representative of two 
independent experiments. ***p ≤ 0.0002.
www.nature.com/scientificreports/
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anti-apoptotic molecule, Bcl-xL was noticed [Fig. 6D]. Bcl-xL plays a vital role in providing a survival signal to 
the cells. No change was seen in the case of STAT-1 [Fig. 6E].
IFG signaling augments the translocation of NF-κB into the nucleus. NF-κ B is responsible for 
cellular growth, inflammatory and immune responses. We observed a significant (p ≤ 0.0002) increase in the 
activation of NF-κ B in H37Ra-Mϕ -IFG [Fig. 6F,G]. Further, experiments were performed that confirmed the 
translocation of NF-κ B by confocal microscopy in IFG stimulated cells [Fig. 6H]. This observation substantiated 
EMSA data [Fig. 6F]. Overall, this finding signifies that induction of autophagy in IFG stimulated macrophages 
operates through NF-κ B, STAT-3 and Akt-PI3K pathways [Fig. 7].
Discussion
There is an urgent need and a challenge to discover new drugs to treat TB because the disease continues to kill 
millions of people annually. Further, despite of the availability of potent drugs, the current regime remains quite 
complicated due to lengthy treatment, side effects and emergence of drug-resistant strains of Mtb.
Type 1 IFNs (IFN-α /β ) are produced by macrophages, plasmacytoid DCs, fibroblasts and endothelial cells and 
play crucial effector function in viral infections34,40. Undeniably, previous references have indicated the efficiency 
of the IFNs therapy in treating yellow fever, chronic hepatitis B (HBV), hepatitis C (HCV) and ebola virus infec-
tions41,42. They augment the synthesis of several key antiviral mediators, including 2′ -5′ oligoadenylate synthetase 
(2′ -5′ A synthetase) and protein kinase R43,44. Further, type 1 IFNs upregulate CXCL10 expression in Mtb infected 
dendritic cells, which could be important to induce the homing and recruitment of cells to the granulomas45.
Considering the importance of IFN-α /β in activating cells of the immune system and bolstering immunity, a 
synthetic interferon IFG-α 2b, which is known as Infergen (IFG) was synthesized46–48. Infergen has been reported 
to upregulate MHC-I expression and enhance the presentation of viral peptides by APCs. As a result, it enhances 
the activation and cytolytic activity of CD8+ cytotoxic T lymphocytes (CTLs)49–51. Further, like IFN-α /β , IFG 
exhibits an optimized affinity for IFNAR and augments the survival and activation of neutrophils, macrophages, 
Figure 7. Proposed model of signaling pathway induced by IFG in the Mtb infected macrophages. It has 
been reported that IFG binds to IFNAR-2 and activates the tyrosine kinase Jak-1 and Tyk-2. Jak-1 induces and 
stimulates the phosphorylation of STAT-3 [pSTAT-3]38,39. We investigated the role of IFG mediated signaling 
mechanism in activating macrophages to restrict the intracellular growth of Mtb. [1] The phosphorylation of 
STAT-3 is induced by Jak-1. [2] Subsequently, Akt is activated through STAT-3 along with PI3K. [3,4] This 
signaling translocates NF-κ B into the nucleus and upregulates the IL-6 secretion, which receives a feed-back 
mechanism through pSTAT-3, Akt and therefore induces autophagy. Thus, ensuring the activation and survival 
of the Mtb infected macrophages. [5] The induction of autophagy in the Mtb infected macrophages directly 
involved in the killing of Mtb. [6] We propose that pSTAT-3 binds to the promoter sequence of INOS gene to 
produce ions in the cytosol that generates NO, a potent antimicrobial agent that may ultimately restrict the 
growth of Mtb. The data were validated by blocking the Akt-PI3K, iNOS and autophagy with their respective 
inhibitors to establish the role of autophagy in restricting the growth of Mtb by IFG stimulated macrophages. 
[7] Blocking of the Akt-PI3K, iNOS (NM), autophagy (3MA|CQ) with their specific inhibitors and therefore 
substantial reduction in the secretion of NO and autophagy, as well as increase in the survival of Mtb signifies 
that autophagy is directly involved in the killing of Mtb. Signifying that the function of iNOS and autophagy are 
interlinked. Overall, this mechanism illustrates that IFG plays a key role in controlling the survival of Mtb inside 
macrophages.
www.nature.com/scientificreports/
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DCs, NK cells, B cells and CD8 T cells31–35,52. Furthermore, it is reported that IFG activates various cell types to 
endorse viral clearance by promoting apoptosis of infected cells34,52. Unfortunately, nothing has been reported 
regarding the role of IFG against Mtb.
In the past, regular efforts have been made to investigate the impact of new molecules or delineate novel role of 
previously established molecules in the treatment of TB. Therefore, keeping in view the above-mentioned reports, 
we thought to evaluate the impact of IFG on the activation of macrophages and inhibition of the intracellular 
survival of Mtb. Following major findings have emerged from our study. IFG significantly i) inhibited the growth 
of Mtb in the macrophages; ii) augmented the secretion of IL-6 and IFN-γ ; iii) upregulated the expression of 
HLA-DR and costimulatory molecules CD80 and CD86; iv) enhanced phagocytic potential of macrophages; v) 
enhanced CD8 T cell mediated target lysis; vi) the mechanism elucidated in curbing the survival of Mtb was 
through the involvement of nitric oxide and autophagy; vii) signaling pathway induced by IFG was through 
phosphorylation of STAT-3, Akt and activation of NF-κ B.
For the optimum activation of T cells, two signals are required. First is the occupancy of T-cell receptor (TCR) 
by MHC-peptide complex. Second signal is also APCs driven in the form of costimulatory molecules like CD80 
and CD86. In the absence of second signal, T cells undergo anergy, i.e. a state of unresponsiveness. Upregulation 
of HLA-DR, CD80 and CD86 by IFG indicate its potential role in the optimal activation of T cells. Further, it 
will help in counteracting Mtb-mediated downregulation of costimulatory molecules and thereby avoiding T 
cell anergy23. IFG predominantly promotes the generation of Th1 cells and CD8 T cells32,49–51. Both these cells 
are responsible for cell mediated immunity and play a cardinal role in protection against Mtb. CD8 T cells lyse 
the infected cells and release the intracellular Mtb. The IFN-γ secreted by Th1 cells activate macrophages and 
consequently they phagocytose and eliminate the bacterium. It was an exciting observation that IFG elicited mac-
rophages showed enhanced phagocytosis and killing of Mtb. These results reveal a novel role of IFG against Mtb.
IFN-α /β interacts with IFNAR receptor and induces the activation of Jak-1 and Tyk-2. Jak-1 stimulates 
and phosphorylates STAT-338,39. Consequently, Akt-PI3K is activated through STAT-3 and translocates into 
the nucleus. Further, Akt-PI3K-STAT-3 signaling helps in delivering survival signal through the activation of 
NF-κ B38,39. Like IFN-α /β , IFG [(IFN)-α 2b] also exhibits a specific affinity for IFNAR and activates tyrosine kinase 
Jak-1 along with Tyk-238,39,52,53. It is also important to mention that signaling through IL-6 also follows the gp130/
Jak/STAT pathway54. We investigated the signaling mechanism mediated by IFG in activating macrophages to 
restrict the intracellular survival of Mtb. We observed that Mtb infected macrophages when activated with IFG 
showed release of IL-6, but no noticeable change was seen in IL-1β, TGF-β, IL-10, TNF-α genes except IL-6 gene 
expression and subsequent phosphorylation of STAT-3 and Akt but not STAT-1. This indicates that IL-6 pathway 
is involved in IFG signaling. Phosphorylation of STAT-3 and Akt-PI3K delivers a survival signal to macrophages 
through upregulation of Bcl-xL and activation of NF-κ B, thereby ensuring cell survival, activation and induction 
of autophagy. We speculate that STAT-3 binds to a promoter sequence of INOS gene, enhances the synthesis of 
iNOS and therefore production of NO that ultimately leads to the killing of Mtb [Fig. 7]. The data were validated 
by blocking the Akt-PI3K, iNOS and autophagy by their respective inhibitors to establish the role of autophagy 
in restricting the growth of Mtb by IFG stimulated macrophages. Blocking of Akt-PI3K, iNOS and autophagy, 
and substantial reduction in the secretion of NO and autophagy, as well as increase in the survival of Mtb sig-
nifies that autophagy is directly involved in the killing of Mtb. Further, the function of iNOS and autophagy are 
interlinked with each other. This provides the unambiguous evidence of a possible mechanism operating in con-
straining the Mtb growth. It has been reported that NO suppresses mTOR expression, which leads to autophagy55. 
Corroborating with this observation, we hypothesize that NO directly suppresses the expression of mTOR, as 
shown by the enhancement of NO release by mTOR inhibitor rapamycin (autophagy inducer), which led to the 
induction of autophagy in Mtb infected and IFG stimulated human macrophages. In essence, this study provides 
a novel immunomodulatory and therapeutic role of IFG against intracellular pathogen Mtb, which may have 
enough potential in future to treat TB patients.
Materials and Methods
Ethics statement. This study was permitted by the Institutional Biosafety and Ethical Committees of 
Institute of Microbial Technology, Chandigarh, India. All blood related work and experimental protocols were 
approved by the Institutional Biosafety and Ethical Committees of Institute of Microbial Technology, Chandigarh 
for project license IBSC8/IMT/10.7.12, and ethical guidelines for biomedical research on human subjects by 
Central Ethics Committee on Human Research (CECHR), ICMR-2000. Human blood was collected from healthy 
volunteers. The informed consent was obtained from all volunteers.
Reagents. Human Infergen was a kind gift from Dr. Eleanor Fish, The Department of Immunology, 
University of Toronto, Toronto, Canada.
THP-1 monocytes (ATCC TIB 202) were differentiated into macrophages by PMA (phorbol-12-myristate-
13-acetate) (Calbiochem, San Diego, CA) for 16 h. The cells were washed 3x and rested for next 16 h in RPMI-
1640 (GIBCO Invitrogen Corporation, Grand Island, NY) medium supplemented with FBS (10%), L-glutamine 
(2 mM), HEPES (10 mM), sodium bicarbonate (2.2 mg/ml), penicillin (0.7 mg/ml), streptomycin (1 mg/ml) at 
37 °C/5% CO2. Human PBMCs were activated with PHA (2 μ g/ml) (phytohemagglutinin PHA-M, Sigma-Aldrich, 
St. Louis, MO).
All the chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO) or otherwise mentioned. 
Free or fluorochrome conjugated antibodies (Abs): CD8-FITC, CD40 FITC, CD80-PE and PerCPefluor710, 
CD19-FITC, CD86-PE, HLA-DR-FITC and PEcy7, CD11b-APC, HLA-DR-PerCP 5.5, CD25-APC-Cy7 and the 
reagents used for cytokine ELISA were purchased from BD Pharmagin (San Diego, CA) and eBioscience (San 
Diego, CA). Fetal bovine serum (FBS) was purchased from Biological Industries (Kibbutz Beit Haemek 25115, 
Israel) and GIBCO (Grand Island, NY). L-pyruvate, L-glutamine, streptomycin and penicillin were from Serva 
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(Heidelberg, Germany). Tissue culture grade plastic-ware was purchased from BD Biosciences (Bedford, MA). 
Abs used in Western blotting against pAkt (Thr308) [C31E5E], Akt (Pan) [C67E7] and PI3 kinase p85 (19H8) 
[4257] were purchased from Cell Signaling Technology (Danvers, MA). Abs to pSTAT-3 (pY705) [612357], 
STAT-3 [610190], pSTAT-1 (pY701) [612132] and STAT-1 [610115] were procured from BD Biosciences 
(Bedford, MA) and iNOS [Ab3523] from Abcam (Cambridge, UK). Inhibitors against STAT-3 [S3I-201], PI3K 
[Ly294002] were bought from Sigma Aldrich (St. Louis, MO), and Akt [Akt inhibitor IV, 124011], iNOS [NM, 
475886] and NF-кB [481408] from Calbiochem (Billerica, MA). The GFP+ Mtb-H37Ra was a kind gift from Dr. 
Pawan Gupta, CSIR-Institute of Microbial Technology, Chandigarh, India.
Activation of THP-1 cells by IFG. THP-1 monocytes (3 × 105/well) were differentiated in 24 well plate with 
PMA (25 ng/ml) for 16 h. The cells were washed and then rested for next 16 h. Later, cells were stimulated with 
different concentrations of IFG (0–64 ng/ml) for 24 h.
T cell proliferation. PBMCs (1.5 × 105 cells/well) isolated from human blood by ficoll-diatrizoate 
(Histopaque-1077, Sigma-Aldrich, St. Louis, MO) density gradient centrifugation method were stimulated with 
PHA (2 μ g/ml) and cultured with different concentrations of IFG (0–64 ng/ml) for 48 h in 96 well U-bottom plate. 
Later, 3H-thymidine (0.5 mCi/well) (Perkin Elmer, MA) was incorporated into the cultures and incubated for 
additional 16 h. Subsequently, the culture plates were harvested on glass-fiber filter mats by a Tomtec Harvester-96 
(Hamden, CT). The radioactivity incorporated was measured using β-scintillation counter (Wallac-1450 
Microbeta Trilux, Perkin Elmer, Waltham, MA) and expressed as counts per minute (cpm).
The activation of macrophages, B cells and T cells by IFG. PBMCs (2.5 × 105/well) were stimulated 
with IFG (64 ng/ml) in the presence or absence of PHA for 48 h. Later, cells were harvested and stained with 
fluorochrome conjugated Abs to detect the activation of macrophages (CD11b+/CD80+/CD86+/HLA-DR+), B 
cells (CD19+/CD80+/CD86+/HLA-DR+) and CTLs (CD8+/CD25+) and their isotype matched control Abs for 
30 min/4 °C. Usual procedures of incubation and washings were followed at each step. Finally, cells were fixed in 
paraformaldehyde (1%). The flow cytometry data were acquired using FACS Calibur and FACS Aria-II and ana-
lyzed by DIVA and Flowjo softwares (BD Biosciences, San Jose and Williamson Way, Ashland, OR).
Mycobacterial uptake by IFG stimulated macrophages. THP-1 monocytes (3 × 105/well) were differ-
entiated with PMA (25 ng/ml) for 16 h, followed by resting for additional 16 h in 24 well plate. Later, macrophages 
were stimulated with IFG (64 ng/ml) for 24 h in RPMI-FBS-10% at 37 °C/5% CO2. After 24 h, IFG stimulated cells 
were infected with Mtb strains H37Rv or H37Ra at MOI (1:5) for 4 h (3 h for M. smegmatis). This was followed by 
incubation with amikacin (2 μ g/ml) for 1 h to kill extracellular bacteria. After 1 h, cells were lysed with saponin 
(0.1%) and lysate (100 μ l) was plated on 7H11 agar plates. Bacterial colonies were enumerated on 21d. All subse-
quent experiments were performed with strain H37Rv (Mtb) or otherwise indicated.
Phagocytosis of GFP+ Mtb by IFG stimulated macrophages by confocal microscopy. 
Macrophages (3 × 105/well) were stimulated as mentioned above with IFG for 24 h. Later, cells were infected with 
GFP+ Mtb (H37Ra) [MOI:1:10] for 4 h. The amikacin (2 μ g/ml) treatment was given for 1 h to kill the extracellu-
lar bacteria, followed by extensive washing with cold PBS. Subsequently, cells were fixed with paraformaldehyde 
(1%) for 10 min. These cells were washed and placed in poly-L lysine pre-coated cover slips and imaged using 
Nikon A1 confocal laser microscope (Nikon, Tokyo, Japan). Z-stacks and extent of GFP+ Mtb internalization 
were monitored among experimental and control samples. The analysis of the intensity of surface plots was per-
formed using Nikon NIS-AR 4.1 image analysis software (Nikon, Melville, NY). The confocal results were further 
validated by flow cytometry and analysis was done by FACS Suite software (BD Biosciences, San Jose).
Intracellular killing of Mtb by IFG stimulated macrophages. Macrophages were infected with Mtb 
(H37Rv or H37Ra) at MOI (1:10) for 4 h in 24 w plates, followed by extensive washings with PBS (1X) to remove 
extracellular bacteria. Later, cells were cultured in antibiotic free RPMI + FBS-10% along with IFG (0–64 ng/ml) 
for 24 h. Amikacin (2 μ g/ml) was added to the cultures to kill the extracellular Mtb. After 24 h, cells were lysed 
with saponin (0.1%) and lysate (100 μ l) was plated on 7H11 agar plate. Colonies were enumerated on 21d.
Cell culture and estimation of cytokines. THP-1 macrophages (2.5 × 105/w) and macrophages 
(2.5 × 105/w) isolated from the human PBMCs by adhering on tissue culture grade petri plates for 4–6 h were cul-
tured with IFG (0–64 ng/ml) in 48 w plates for 48 h. The control cells were cultured in medium alone. The super-
natants were collected after 24 h and IL-6 and IFN-γ were estimated. Briefly, 96 w plates were coated O.N/4 °C 
with Abs to human IL-6 (2 μ g/ml) and IFN-γ (2 μ g/ml) in phosphate buffer (pH 9.2, 0.01M). The unbound sites 
were blocked with BSA (1%) in PBS (1X) for 3 h/RT. Subsequently, respective recombinant cytokines as standard, 
and culture supernatants (50 μ l volume) were added and incubated ON/4 °C. Later, biotinylated anti-human IL-6 
(2 μ g/ml) and IFN-γ (2 μ g/ml) Abs diluted (1:1) in PBS-Tween buffer were added into the plates and incubated for 
2 h/RT. Next, avidin-HRP (1:10,000) was added and incubated at 37 °C/45 min. The regular procedures of washing 
and incubation were followed at each step. The color was developed using H2O2-OPD substrate-chromogen. The 
reaction was stopped by H2SO4 (7%) after 20 min. The plates were read at 492 nm. The results expressed as pg/ml 
of secreted cytokines were calculated using serial log2 dilutions of standard curve drawn with rIL-6 and rIFN-γ .
Viability of IFG treated macrophages. Macrophages were stimulated with IFG (0–64 ng/ml) for 24 h at 
37 °C in RPMI-FBS-10% (500 μ l) in 48 w plates. The stimulated cells were harvested, washed and resuspended 
in PBS and stained with 5 μ l/tube annexin V and 2.5 μ l/tube of propidium iodide (50 mg/ml). The cells were 
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incubated in the dark for 15 min at RT. Later, PBS (200 μ l) was added to the cells and acquired immediately using 
BD FACS Calibur flow cytometer and analysis was done by DIVA software.
Real time PCR for the quantification of IL-6, ATG5, ATG7, BECLIN-1, INOS, IL-1β, IL-10, TGF-β 
and TNF-α. Total RNA was isolated using trizol reagent from IFG (64 ng/ml) stimulated macrophages for 
6 h, according to the manufacturer’s instruction (Invitrogen, Carisbad, CA). Briefly, RNA was quantified with 
the help of NanoDrop spectrophotometer. A260/A280 ratio of all the samples was in the range of 1.90 to 2.00. 
DNA contamination from RNA samples was removed by amplification grade DNase. RNA samples (3 μ g) were 
incubated with DNase (3U) for 15 min in the reaction buffer. Later, DNase activity was terminated by adding 
stop solution. Further, the samples were heated at 70 °C/10 min to inactivate DNase activity. Analysis was done 
by comparative Ct method, whereas Ct values were normalized against house-keeping control actin. The results 
are represented as relative expression (fold change). The fold change was calculated considering the value of 
uninfected/unstimulated controls as 1. RT-qPCR and data analysis were done by Step One Plus RT-qPCR system 
(Applied Biosystems, Chromos, Singapore). The RT-qPCR primer sequences are as follows:
β-ACTIN primer: β -ACTIN-F 5′ -AGAGGGAAATCGTGCGTGAC-3′ 
        β -ACTIN-R 5′ -CAATAGTGATGACCTGGCCGT-3′ 
IL-6 gene primer: CIL-6-H F 5′ -AGGAGACTTGCCTGGTGAA-3′ 
        CIL-6-H R 5′ -CAGGGGTGGTTATTGCATCT-3′ 
ATG5 gene primer: ATG5-Fwd 5′ -AGAAGCTGTTTCGTCCTGTGG-3′ 
        ATG5-Rev 5′ -AGGTGTTTCCAACATTGGCTC -3′ 
ATG7 gene primer: ATG7-Fwd 5′ -AATGTCTGCTGCTTGGAGCC -3′ 
        ATG7-Rev 5′ -ACCCCCTAGGCAATCTTCAAA -3′ 
BECLIN-1 gene primer: BECLIN1-Fwd 5′ -ACCTCAGCCGAAGACTGAAG -3′ 
          BECLIN1-Rev 5′ -AACAGCGTTTGTAGTTCTGACA -3′ 
INOS gene primer: EiNOS-H F 5′ -ACAAGCCTACCCCTCCAGA-3′ 
        EiNOS-H R 5′ -TCCCGTCAGTTGGTAGGTTC-3′ 
IL-1β gene primer: hIL-1β -RT F 5′ -GGACAAGCTGAGGAAGATGC-3′ 
        hIL-1β -RT R 5′ -TCGTTATCCCATGTGTCGAA-3′ 
TGF-β gene primer: CTGF-B1H F 5′ -CTGGAAACCCACAACGAAA-3′ 
         CTGF-B1H R 5′ -AACTTGAGCCTCAGCAGAC-3′ 
TNF-α gene primer: hTNFα -RT F 5′ -CACCATGAGCACTGAAAGCA-3′ 
          hTNFα -RT R 5′ -CGAGAAGATGATCTGACTGCCT-3′ 
IL-10 gene primer: hIL10-RT F 5′ -GAGAACAGCTGCACCCACT-3′ 
        hIL10-RT R 5′ -CCCAGGTAACCCTTAAAGTCC-3′ 
Target cell lysis by CD8 T cells. The target cells were prepared using PBMCs labelled with carboxyfluo-
rescein succinimidyl ester (CFSE) (1 μ M) for 8 min/37 °C in PBS (1X). The cells washed 3X with PBS-FCS 1% 
were γ -irradiated (3000R). Allogeneic PBMCs were isolated from second donor and T cells were purified and 
stimulated with IFG. Later, target and effector cells were cocultured (1:2 ratio). The percentage of CFSE-labeled 
PBMCs lysed by CD8 T cells were analyzed by flow cytometry. The formula was used to analyze specific lysis: 
ratio = (mean percentage of CFSEhi cells/mean percentage of CFSElo cells), and the percentage of specific 
lysis = [1 − (ratio for CFSEhi cells/ratio for CFSElo cells)] × 100.
Nitric Oxide (NO) production. Macrophages were infected with Mtb for 4 h and stimulated with IFG 
(64 ng/ml) for 24 h. Later on, supernatants were collected and NO was estimated by Griess method36. Briefly, 
supernatants (50 μ l) were incubated with an equal volume of Griess reagent along with sodium nitrite as standard 
for 5–10 min/RT. Later, absorbance was measured at 550 nm. Further, the involvement of NO in IFG signaling 
was authenticated by treating the cells with iNOS inhibitor (NM: N-monomethyl-L arginine) (20 μ M), Akt inhib-
itor IV (20 μ M) and NF-кB inhibitor (50 μ M) for 1 h and stimulated with IFG for 24 h.
Inhibition of iNOS expression by N-monomethyl-L arginine. Mtb infected Mϕ s were stimulated 
with IFG in the presence or absence of iNOS inhibitor (NM: N-monomethyl-L arginine) (20 μ M) for 24 h. Later, 
cells were lysed and CFU plating was done to quantify the viable bacteria.
Cell cultures and Western blotting. The Mtb infected macrophages were incubated with IFG (64 ng/ml). 
Further, to prove specifity, the cultures were treated with specific inhibitors for STAT-3 [S3I-201] (50 μ M), PI-3K 
[Ly294002] (20 μ M), Akt (20 μ M), iNOS [NM] (20 μ M) and autophagy [3MA] (20 mM) for 1 h and stimulated 
with IFG (64 ng/ml) at different time-points [16 h for iNOS, 4 h for LC3B, 15–30 min for STAT-3 | Akt | STAT-1 | 
Bcl-xL | PI3K] in 12 w plate. Cells stimulated with LPS (2 μ g/ml) were used as a positive control. These cells were 
then harvested, washed, and lysed in lysis buffer (Cytoplasmic protein extraction buffer, phosphatase and protease 
inhibitor cocktail). Later, protein was estimated in the lysate and SDS-PAGE was performed. After transfer to 
PVDF membranes and subsequent blocking, the membranes were immunoblotted using Abs to phosphorylated 
and non-phosphorylated form of STAT-3, Akt, STAT-1 and PI3K. Blots were also incubated with Abs against 
LC3B, Bcl-xL, iNOS and loading control actin. Blots were developed using a chemiluminescence kit (Amersham 
Pharmacia Biotech, Buckinghamshire, UK) (ECL; Pharmacia-Amersham, Freiburg, Germany). Scanning of the 
blots was done by ImageQuant LAS 4000 (GE Healthcare, Freiburg, Germany). Image analysis was performed 
with MultiGuage image and ImageJ analysis softwares.
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Quantification of autophagy influx by confocal microscopy. The THP-1 macrophages were infected 
with GFP-H37Ra for 4 h and stimulated with IFG (64 ng/ml) and rapamycin [1 μ M] for another 4 h. Mtb-Mϕ -IFG 
were fixed on poly-L-lysine coated cover slips for 15 min. Later, cells were fixed with paraformaldehyde (2x) for 
10 min followed by treatment with triton X100 (0.1%) for 3 min. The non-specific sites on cells were blocked with 
BSA (2%) for 2 h. This was followed by incubation with rabbit anti-human LC3 Ab for 2 h. Subsequently, cells 
were incubated with Alexa Fluor 633-anti-rabbit Ab for 1 h and followed by staining with DAPI dye. Regular 
washings were followed at each and every step. The cells were imaged through confocal microscopy. Rapamycin 
was used as a positive control. Number of puncta formation was counted manually from 4–5 different micro-
scopic field. Percent of cells with LC3 puncta were presented in bar diagram.
Demonstration of NF-κB by EMSA. Macrophages were cultured with IFG for 30 min. Later, the cells were 
harvested and nuclear extract was prepared for EMSA. Briefly, an equal amount of nuclear extract (3 μ g) from 
each sample was incubated for 20 min/37 °C in water bath with [32P] end labeled duplex oligonucleotides contain-
ing binding site for NF-κ B. The DNA–protein complexes were resolved by electrophoresis on a native PAGE-gel 
(7%). After electrophoresis, the native gel was dried and exposed to screen at RT for 6–10 h and scanned by 
phospho-imager (Fujifilm, Tokyo, Japan).
The translocation of NF-κB by confocal microscopy. Mϕ IFG were fixed on poly-L-lysine (0.1%) 
coated cover slips for 15 min. Later, cells were fixed with paraformaldehyde (2x) for 10 min followed by treat-
ment with triton X100 (0.1%) for 3 min. The non-specific sites were blocked with BSA (2%) for 2 h. It was fol-
lowed by incubation with mouse anti-human NF-κ B p65 Ab for 2 h. Subsequently, cells were incubated with 
FITC-anti-mouse Ab for 1 h and followed by staining with Hoechst dye. Regular washings were followed at each 
step. The cells were imaged through Nikon A1 confocal laser microscope (Nikon, Tokyo, Japan) and analysis was 
performed using Nikon NIS-AR 4.1 image analysis software (Nikon, Melville, NY).
Statistics. The data analysis was done by Student’s ‘t’ test, non-parametric Mann-Whitney two tailed and 
repeated measure ANOVA with post Student-Newman-Keuls multiple comparison test using Graph Pad InStat 
3 and Graph Pad Prism 6 softwares.
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